Table 1.
Clinical characteristics and circulating CILP-2 levels in study subjects.
| Item | NGT (n = 105) | IGT (n = 102) | T2DM (n = 103) |
|---|---|---|---|
| Age (year) | 52.3 ± 9.6 | 54.1 ± 10.8 | 55.0 ± 11.5 |
| Males/females | 36/69 | 41/61 | 41/62 |
| BMI (kg/m2) | 23.7 ± 3.3 | 24.0 ± 3.1 | 24.7 ± 3.1* |
| WHR | 0.87 ± 0.06 | 0.90 ± 0.05** | 0.91 ± 0.06** |
| FAT (%) | 30.40 ± 8.46 | 30.79 ± 6.70 | 30.88 ± 8.40 |
| SBP (mmHg) | 119.1 ± 16.9 | 123.4 ± 16.2* | 127.1 ± 16.3** |
| DBP (mmHg) | 74.3 ± 10.5 | 77.1 ± 9.15* | 79.2 ± 9.6** |
| TG (mmol/L) | 1.23 (0.90–1.81) | 1.33 (0.98–1.93) | 1.75 (1.24–2.27)**,†† |
| TC (mmol/L) | 4.84 ± 1.19 | 5.06 ± 1.07 | 5.15 ± 0.98* |
| HDL-C (mmol/L) | 1.33 ± 0.30 | 1.29 ± 0.32 | 1.28 ± 0.26 |
| LDL-C (mmol/L) | 3.00 ± 0.80 | 3.00 ± 0.88 | 3.06 ± 1.08 |
| FFA (umol/L) | 0.54 ± 0.21 | 0.54 ± 0.30 | 0.61 ± 0.26*,† |
| FBG (mmol/L) | 5.00 ± 0.61 | 5.77 ± 0.75** | 9.16 ± 4.35**,†† |
| 2h-BG (mmol/L) | 6.12 ± 1.13 | 9.19 ± 0.98** | 17.52 ± 7.13**,†† |
| FIns (mU/L) | 6.90 (5.10–9.60) | 8.69 (6.10–12.49)** | 9.20 (5.95–13.17)** |
| 2h-Ins (mU/L) | 36.5 (17.0–54.5) | 70.5 (54.2–112.9)** | 52.9 (23.1–82.4)**,†† |
| HbA1c (%) | 5.74 ± 0.55 | 5.95 ± 0.48** | 7.92 ± 2.40**,†† |
| HOMA-IR | 1.75 ± 0.95 | 2.68 ± 1.70** | 3.97 ± 2.41**,†† |
| HOMA-IS | 96.2 (55.9–147.6) | 80.1 (59.7–127.4) | 46.3 (21.7–68.8)**,†† |
| CILP-2 (ng/L) | 126.1 ± 40.7 | 156.7 ± 68.4** | 209.4 ± 142.2**,†† |
| CILP-2 (adjusted)§ | 126.4 ± 9.4 | 156.1 ± 9.9** | 209.0 ± 9.6**,†† |
Values are given as mean ± SD or median (interquartile range). §Mean ± standard error by general linear model with adjustment of age, gender, and BMI. *P < 0.05, **P < 0.01 compared with NGT group; †P < 0.05, ††P < 0.01 compared with IGT group.